Tandem Diabetes (NASDAQ: TNDM) reported Q4 non-GAAP EPS of ($0.01), $0.06 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $223.4 million versus the consensus estimate of $221.6 million.

GUIDANCE:

Tandem Diabetes sees FY2023 revenue of $885-900 million, versus the consensus of $891.55 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.